ONCAlert | Upfront Therapy for mRCC
Videos  >  

Molecular Profiling in NSCLC

Fabrice Barlesi, MD
Published Online:8:17 PM, Mon October 1, 2018

Fabrice Barlesi, MD, head of the Multidisciplinary Oncology and Therapeutic Innovations Department at Aix-Marseille University and the Assistance Publique Hôpitaux de Marseille, France, discusses the importance of molecular testing in patients with nonsquamous non–small cell lung cancer (NSCLC) during the World Conference on Lung Cancer (WCLC) in Toronto, Canada.

In this patient population, Barlesi recommends testing for at least 4 biomarkers, including EGFR, ALK, ROS1, and BRAF. He says there are now clear signs of efficacy with additional biomarkers, as well.

Barlesi says results were presented at this year’s WCLC meeting for patients withRET, NTRK, and TRK rearrangements. The field continues to grow rapidly with many approved drugs, as well some that have received a breakthroughdesignation from the FDA.

Barlesi stressed the importance of screening patients using multiplex mutation testing, and especially next-generation sequencing. It is important to look at both DNA, as well as RNA, to identify the mutations and rearrangements, he says.
Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.